Treatment options for human immunodeficiency virus-infected pregnant women

R. S. Sperling, P. Stratton, A. Bardeguez, D. Cotton, H. E. Fox, D. J. Gloeb, B. Gonik, D. V. Landers, H. Minkoff, J. Mitchell, M. J. O'Sullivan, R. R. Viscarello, D. H. Watts

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalObstetrics and Gynecology
Volume79
Issue number3
StatePublished - Mar 9 1992
Externally publishedYes

Fingerprint

Pregnant Women
HIV
Anti-Retroviral Agents
Pregnancy
Pneumocystis Pneumonia
Zidovudine
Opportunistic Infections
Seroepidemiologic Studies
Secondary Prevention
Obstetrics
Motivation
Counseling
Acquired Immunodeficiency Syndrome
Therapeutics
Physicians

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Sperling, R. S., Stratton, P., Bardeguez, A., Cotton, D., Fox, H. E., Gloeb, D. J., ... Watts, D. H. (1992). Treatment options for human immunodeficiency virus-infected pregnant women. Obstetrics and Gynecology, 79(3), 443-448.

Treatment options for human immunodeficiency virus-infected pregnant women. / Sperling, R. S.; Stratton, P.; Bardeguez, A.; Cotton, D.; Fox, H. E.; Gloeb, D. J.; Gonik, B.; Landers, D. V.; Minkoff, H.; Mitchell, J.; O'Sullivan, M. J.; Viscarello, R. R.; Watts, D. H.

In: Obstetrics and Gynecology, Vol. 79, No. 3, 09.03.1992, p. 443-448.

Research output: Contribution to journalArticle

Sperling, RS, Stratton, P, Bardeguez, A, Cotton, D, Fox, HE, Gloeb, DJ, Gonik, B, Landers, DV, Minkoff, H, Mitchell, J, O'Sullivan, MJ, Viscarello, RR & Watts, DH 1992, 'Treatment options for human immunodeficiency virus-infected pregnant women', Obstetrics and Gynecology, vol. 79, no. 3, pp. 443-448.
Sperling RS, Stratton P, Bardeguez A, Cotton D, Fox HE, Gloeb DJ et al. Treatment options for human immunodeficiency virus-infected pregnant women. Obstetrics and Gynecology. 1992 Mar 9;79(3):443-448.
Sperling, R. S. ; Stratton, P. ; Bardeguez, A. ; Cotton, D. ; Fox, H. E. ; Gloeb, D. J. ; Gonik, B. ; Landers, D. V. ; Minkoff, H. ; Mitchell, J. ; O'Sullivan, M. J. ; Viscarello, R. R. ; Watts, D. H. / Treatment options for human immunodeficiency virus-infected pregnant women. In: Obstetrics and Gynecology. 1992 ; Vol. 79, No. 3. pp. 443-448.
@article{9956994550b94ad38d7c3c362e861166,
title = "Treatment options for human immunodeficiency virus-infected pregnant women",
abstract = "The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.",
author = "Sperling, {R. S.} and P. Stratton and A. Bardeguez and D. Cotton and Fox, {H. E.} and Gloeb, {D. J.} and B. Gonik and Landers, {D. V.} and H. Minkoff and J. Mitchell and O'Sullivan, {M. J.} and Viscarello, {R. R.} and Watts, {D. H.}",
year = "1992",
month = "3",
day = "9",
language = "English",
volume = "79",
pages = "443--448",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Treatment options for human immunodeficiency virus-infected pregnant women

AU - Sperling, R. S.

AU - Stratton, P.

AU - Bardeguez, A.

AU - Cotton, D.

AU - Fox, H. E.

AU - Gloeb, D. J.

AU - Gonik, B.

AU - Landers, D. V.

AU - Minkoff, H.

AU - Mitchell, J.

AU - O'Sullivan, M. J.

AU - Viscarello, R. R.

AU - Watts, D. H.

PY - 1992/3/9

Y1 - 1992/3/9

N2 - The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.

AB - The increasing seroprevalence of human immunodeficiency viruis (HIV) among women of reproductive age and the risks of vertical transmission of HIV have led to recommendations for routine prenatal HIV counseling and testing. The incentive to undergo such testing is related not only to fetal concerns, but also to the potential benefit of early and comprehensive therapy for women. Treatments that should be considered for use during pregnancy include the antiretroviral agent zidovudine and prophylactic agents to prevent Pneumocystis carinii pneumonia, the most common opportunistic infection seen in patients progressing to AIDS. Assessment of the risks and benefits of these treatments during pregnancy is complex and requires discussions between physician and patient. This paper reviews current information and provides recommendations for incorporating therapies into obstetric practice.

UR - http://www.scopus.com/inward/record.url?scp=0026606544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026606544&partnerID=8YFLogxK

M3 - Article

C2 - 1738529

AN - SCOPUS:0026606544

VL - 79

SP - 443

EP - 448

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 3

ER -